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Summary We have measured the serum concentration of the acute phase reactant, C-reactive protein (CRP),
in 20 patients with histologically proven small cell lung cancer undergoing their first pulse of induction
cytotoxic chemotherapy. Baseline CRP concentrations were raised in 16 of 20 patients (median baseline CRP
18.5 mg-1; normal range <OmgI-). CRP levels more than doubled in 11 of 20 patients during induction
chemotherapy. This acute phase reaction was seen in seven of the 10 chemosensitive patients, but was not
observed in any of the five non-responding patients. Five patients were non-evaluable for chemoresponse.
These data indicate that there is a previously undescribed quantifiable acute phase response during
chemotherapy for small cell lung cancer which has potential for predicting chemoresponse.
The serum concentration of the acute phase reactant C-
reactive protein (CRP) is raised in inflammatory reactions
and tissue destruction (Cooper & Milford Ward, 1979;
Fischer & Gill, 1976; Powell, 1979) and also in malignant
disorders (Baruah & Gogoi, 1975; Cooper & Milford Ward,
1979; Cooper & Stone, 1979; Cooper & O'Quigley, 1982;
Raynes & Cooper, 1983). Furthermore, C-reactive protein
concentrations have been used to monitor disease activity in
both inflammatory (Amos et al., 1977) and malignant
diseases (Harshman et al., 1974; Rosenthal & Sullivan,
1979).
Patients with small cell lung cancer are often responsive to
chemotherapy and it is from the group that shows the best
initial response that long-term survivors may result. As such
it would clearly be useful to be able to predict overall
response to treatment at an early stage during treatment.
We hypothesised that in patients with chemosensitive
tumours, treatment might result in tumour necrosis which
would induce an acute phase reaction that could be
quantified by serial measurement of CRP concentrations.
Conversely, there would be little or no tumour necrosis
during chemotherapy in patients with inherently resistant
tumours and hence no evidence of an acute phase reaction in
these patients. Therefore, we have measured CRP levels in
20 patients with small cell lung cancer receiving their first
pulse of intravenous cytotoxic induction chemotherapy to
assess if there is evidence of an acute phase response to such
treatment and to relate this to subsequent tumour regression.
Patients and methods
Twenty patients all with a histologically proven diagnosis of
small cell lung cancer (15 limited, 5 extensive disease) were
studied. All patients received 4 cycles of treatment with
cyclophosphamide (750mg m 2), adriamycin (40mg m 2)
and vincristine (1.6mgm-2) on day 1 and etoposide
(75 mg m 2) on days 1-3, repeated at 3-weekly intervals.
Formal restaging by repeat clinical, radiological and
bronchoscopic examinations (after approximately 12-15
weeks) demonstrated that seven patients (all with limited
disease) had a complete response (CR), three a partial (> 50%
tumour regression) response (PR), and five no response
(NR) to treatment. Five patients were non-evaluable for
response: three toxic deaths, one other death, one declined
further chemotherapy.
Blood samples (10ml) were obtained for measurement of
CRP level before chemotherapy and at daily intervals for a
minimum of 3 days during the first pulse of induction
chemotherapy. Samples were immediately centrifuged and
serum separated and frozen at -20'C before analysis.
Analysis was performed by immunonephelometry using the
Hyland laser nephelometer (Whicher et al., 1978). Antisera
and standards were obtained from Atlantic Antibodies
(Scarborough, Maine). Samples were pre-precipitated with
4% polyethylene glycol 6,000 in phosphate buffer
(10mmoll-1, pH 7.0), to reduce background turbidity. The
co-efficient of variation for the assay (both intra- and inter-
batch) was less than 10%.
Results
Baseline CRP concentrations were raised in 16 of 20 patients.
Median baseline CRP was 18.5mgl-1 (normal range
<l0mg1-1). There was no significant difference in median
baseline levels in those patients with limited (19mg1-1) and
extensive (18mg1-1) disease.
In 11 of 20 patients CRP levels rose significantly and more
than doubled. These changes during chemotherapy are
illustrated in Figure 1, which shows a pattern of rising CRP
with a peak at 72h. Such acute phase changes in CRP were
seen in seven of the 10 patients who responded to
chemotherapy, and in four of the five non-evaluable patients.
These elevated patterns were in contrast to the flat profiles
(illustrated in Figure 2) which were observed in all five non-
responding patients (P<0.05, x2 test with Yate's correction).
Median baseline CRP and median CRP concentrations at
72h for each group of patients, sub-divided according to
chemoresponse, are shown in Table I. This shows a
significant peak in CRP at 72h in both complete response
(P<0.01) and partial response (P<0.01) groups, analysed by
Wilcoxon matched test. In contrast there was no significant
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Figure 1 An acute phase reaction during chemotherapy was
seen in 11/20 patients (7/10 chemoresponsive and 4/5
non-evaluable).
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Figure 2 Flat CRP profiles were seen in all five patients who
did not respond (NR) to chemotherapy.
Table I Median CRP concentrations before and 72 hours after
induction chemotherapy. Patients have been sub-divided according
to chemoresponse
Baseline CRP (mgl- 1) 72h CRP (mgl')
Response median (range) median (range)
Complete (n=7) 17(8-35) 39(8-150)
Partial (n =3) 13(8-30) 36(16-94)
None (n=5) 18(13-31) 27(18-45)
Non-evaluable (n=5) 21(19-41) 68(16-81)
rise from median baseline in the non-responding group of
patients.
Discussion
We found serum concentrations of CRP to be raised in
patients with small cell lung cancer. This is a finding which
is in keeping with published data in other malignant
disorders (Baruah & Gogoi, 1975; Cooper & Milford Ward,
1979; Cooper & Stone, 1979; Cooper & O'Quigley, 1982;
Raynes & Cooper, 1983). However, we did not find an
association between disease extent and baseline CRP
concentrations. This is in contrast to the findings of other
researchers who have reported such an association in the
case of CRP (Cooper & O'Quigley, 1982) and also other
acute phase reactant proteins (Harshman et al., 1974;
Rosenthal & Sullivan, 1979). The reason for this is uncertain
but may relate to the relatively good condition of our
extensive disease patients, all of whom were suitable for
aggressive induction chemotherapy.
An acute tumour lysis syndrome following chemotherapy
has previously been described in a number of different
malignancies (Cadman et al., 1977; Cohen et al., 1980;
Ettinger et al., 1978) including small cell lung cancer
(Vogelzang et al., 1983). This syndrome, characterised by a
number of acute biochemical upsets including
hyperkalaemia, hypocalcaemia and hyperuricaemia is
thought to arise because of chemotherapy induced acute
tumour lysis (or necrosis). We hypothesised that the acute
tumour necrosis in patients with chemosensitive tumours
might induce an acute phase reaction which could be
quantified by serial measurement of CRP concentrations.
This appears to be the case, with seven out of 10
chemoresponsive patients showing a significant rise in CRP.
Interestingly, two of those three chemoresponsive patients
who did not show a rise in CRP following chemotherapy
had baseline CRP levels within the normal range, perhaps
indicating the earlier stage of their tumour. Conversely, in
the five chemoresistant patients there was little or no change
in CRP concentrations during chemotherapy. Figure 2
illustrates the flat CRP profiles seen in all of the five non-
responding patients, presumably a reflection of the reduced
or absent necrosis of the resistant tumour.
Furthermore, it should be noted that two of the three
patients who died because of acute myelosuppression showed
a pronounced rise in CRP concentration with values
quadrupling by 72h. This would also sustain the hypothesis
that severe chemotherapy induced tumour necrosis, with
associated marrow toxicity results in a marked acute phase
reaction at the time of injury and before supervening
infection is manifest.
As far as we are aware such a quantifiable acute phase
reaction following chemotherapy has not been previously
described. One group from Scandinavia (Grutzmeier & Von
Schenck, 1986) has reported no change in CRP levels during
chemotherapy for acute leukaemia. However, these patients
did not have solid tumours, sampling was performed less
frequently and may have missed the sharp rise in CRP
concentrations we have found, and an unusually high upper
limit of CRP was accepted as normal (Milroy et al., 1987).
Although the number of patients in this study is small,
there does appear to be evidence of a previously undescribed
quantifiable acute phase reaction following chemotherapy in
patients with chemoresponsive small cell lung tumours,
which is not apparent in resistant patients. If confirmed in
larger studies, including other solid tumour types, it might be
possible to predict chemoresponse and hence tailor treatment
more closely to individual patients needs.
We thank Mrs Elaine Riley for typing this manuscript, Mr R.
Carter for statistical advice and the Department of Medical
Illustrations, Glasgow Royal Infirmary, for their assistance.
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